Stocks

Despite strong Q4, Dr Reddy’s share drop

Chennai | Updated on May 21, 2020 Published on May 21, 2020

Dr Reddy’s Laboratories Ltd   -  Supplied Pic

Analysts view remain mixed, as some see little headroom for pharma major’s share price

Shares of Dr Reddy’s Laboratories dropped 1.9 per cent on Thursday to close at ₹3,837.05 on the BSE, just above day’s low of ₹3,828.25, despite it came out with a ‘decent’ set of March quarter number on Wednesday. Most analysts, who until now remained negative on the stock and the sector, now have turned cautiously optimistic. While some brokerages see at least 10 per cent rise from the current stock price level, most do not see much headroom for the stock from the current level.

Pharma major Dr Reddy’s has reported a 76 per cent jump in consolidated net profit at ₹764 crore in the fourth quarter ended March 31, 2020, as against ₹434 crore in the same quarter in the previous financial year according to International Financial Reporting Standards (IFRS). Total revenue rose 10 per cent to ₹4,432 crore (₹4,016 crore).

Credit Suisse and CLSA maintained their ‘outperform’ rating on Dr Reddy’s with a price target of ₹4,300 and ₹4,450, respectively, as they expect strong show from company’s US units and better-than-expected cost control to drive its EBIDTA.

Emkay Global upgraded the target price to ₹4,100 (from earlier ₹3,424) on Dr Reddy’s though it retains its ‘hold’ rating. “Dr Reddy’s continues to exhibit strong execution, beating operating profit estimates by 5 per cent, led by strong growth in the US/EU and tight cost control. This is the second consecutive quarter of ₹35+ quarterly EPS and adds to our confidence regarding FY21 estimates,” it added.

Gains from pre-purchases

Motilal Oswal Financial said besides new launches and market share gains posted in existing products across key markets, Dr Reddy’s Lab has benefited from the pre-purchases of medicines by patients in the US market; the company is also making strides in the newer markets in Europe. This has been offset, to some extent, by price erosion in the base business, the domestic broking firm, which maintains a ‘neutral’ rating on Dr Reddy’s, said. It, however, revised its price target to ₹3,775 (from ₹3,490 earlier).

However, for HDFC Securities, it’s still not a ‘buy’. The domestic brokerage maintains its ‘reduce’ rating with a price target of ₹3,770 (up from earlier ₹3,330). According to HDFC Securities, price erosion in the US has stabilised, deflation to continue; gNuvaring and gCopaxone – CRL to be filed in few months; Wockhardt deal closure expected in Q1-FY21; and Covid impact was neutral on revenues.

Dr Reddy’s Q4 performance was largely inline with Phillips Capital estimates. “While we expect Dr Reddy’s to sustain steady growth in its key markets (despite some impact of Covid), it will see margin pressure going ahead as FY20 margins were boosted by the sale of a brand in the US.”

Also, the long-awaited drug opportunities (gCopaxone and gNuvaring) are further delayed (factor as H2 opportunity versus full year earlier), which coupled with the rising R&D spend and enhanced tax-rate guidance will likely weigh on overall earnings, said Phillips Capital, which maintains its ‘neutral’ rating with a target price of ₹3,600 (up from ₹3,300).

Published on May 21, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Sincerely,

Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.